β-Amyrin
Based on 1 Customer Validation
β-Amyrin shows effectively counteract amyloid β (Aβ)-induced impairment of long-term potentiation (LTP). β-Amyrin is a promising candidate for Alzheimer's disease (AD) research. β-Amyrin exhibits anti-inflammatory effects, protective activity against pulmonary fibrosis, and notable antibacterial capabilities. β-Amyrin is an orally active natural triterpenoid compound.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.95%
- CAS No.: 559-70-6
- Formule: C30H50O
- Masse moléculaire:426.72
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
23.55 μM
Compound: 10
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| B16 | ED50 |
>50 μM
Compound: 14
|
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
|
[PMID: 12027734] |
| B16 | IC50 |
48.8 μM
Compound: 14
|
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
|
[PMID: 12027734] |
| DU-145 | IC50 |
27.88 μM
Compound: 10
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| HEK293 | IC50 |
94.4 μM
Compound: 10
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| HeLa | IC50 |
>50 μM
Compound: 4
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 19447618] |
| HeLa | IC50 |
27.94 μM
Compound: 10
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| J774 | IC50 |
>234.3 μM
Compound: 2
|
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
|
[PMID: 17637068] |
| MCF7 | IC50 |
>50 μM
Compound: 4
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 19447618] |
| MCF7 | IC50 |
35.31 μM
Compound: 10
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28482219] |
| SK-MEL-1 | IC50 |
>50 μM
Compound: 4
|
Cytotoxicity against human SK-MEL-1 cells by MTT assay
Cytotoxicity against human SK-MEL-1 cells by MTT assay
|
[PMID: 19447618] |
β-Amyrin (1-100 μM, 0-80 min) blocks Aβ-induced synaptic dysfunction in the hippocampal tissues of mice[1].
β-Amyrin (1-10 μg, 24 h 15 min) shows antioxidant activity in cultured hPBMCs (human peripheral blood mononuclear cells)[2].
β-Amyrin (5-20 μg/mL, 16-24 h) significantly inhibits PGE2 (HY-101952), IL-6 secretion and NF-κB activation dose-dependently in LPS-induced hPBMCs[2].
β-Amyrin (5 μM, 2 h) exhibits antibacterial mode of action, leading promoting apoptosis-like death in E. coli by producing ROS.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:E. coli (BW 25113)
-
Concentration:5 μM
-
Incubation Time:2 h
-
Result:Decreased GSH/GSSG ratio and induced membrane depolarization and DNA cleavage.
Activated caspase-like protein expression.
β-Amyrin (20-100 μg, i.p.) inhibits carrageenan-induced paw edema of rats[2].
β-Amyrin (20-80 mg/kg, i.g., daily, 5 days) has a potent efficacy in protecting against BLM-induced mice pulmonary fibrosis via suppressing inflammatory response and oxidative stress[3].
Pharmacokinetic parameters of β-Amyrin in rats
| β-Amyrin standard IV (group 3) | β-Amyrin standard oral dose (group 2) | ||
| Dose (mg kg−1) | 1 | 3 | 300 (equivalent of 3mg kg−1 β-amyrin) |
| V (ml kg−1) | 1317 | ||
| AUC0→24 h (min μg ml−1) | 411 | 10.6 | 47.3 |
| Cl (ml min−1 kg−1) | 2.04 | ||
| t1/2λZ (h) | 10.2 | 10.3 | 8.3 |
| MRT0→24 h (h) (h) | 8 | 8.5 | 8.7 |
| Cmax (ng ml−1) (h) (h) | 18.7 | 75 | |
| tmax (h) | - | 3 (n = 2) or 5 (n = 1) | 3 (n = 3) or 5 (n = 1) |
| F (%) | 0.86 | 3.83 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CD-1 mice, 26-28 g, 6 weeks old. 5 μL of Aβ was acutely injected into the left lateral ventricle by hand[1].
-
Dosage:4 mg/kg
-
Administration:p.o., daily, 5 days
-
Result:Increased number of transitions between the light and dark compartments.
Increased the total exploration time on the light compartment of the apparatus and the time spent in open arms.
Ameliorated the reduction of neurogenesis.
-
Animal Model:Adult male rats of Sprague–Dawley strain, weighing 150-180 g. Carrageenan induces edema in the hind paw of the rat[2].
-
Dosage:20, 50, 100 μg/kg
-
Administration:i.p.
-
Result:Significant decreased edema by in a dose dependent manner.
-
Animal Model:Adult male rats of Sprague–Dawley strain, weighing 150-180 g. Carrageenan induces Use Bleomycin (BLM) (HY-108345), 5mg/kg, one-time intratracheally injection, in 50μL saline per mouse to induce the marine model of pulmonary fibrosis[3].
-
Dosage:20, 40, 80 mg/kg
-
Administration:i.g., daily, 5 days
-
Result:Promoted the values of SO2 and PO2 and inhibited the value of PCO2.
Significantly improved inflammatory cell infiltration, the thickened alveolar septum and the lesion collapses of the alveoli and formation of flaky lung tissue.
Chemical Information
-
CAS No. 559-70-6
-
Appearance Solid
-
Masse moléculaire 426.72
-
Formule C30H50O
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])CC(C)(C)CC[C@@](C)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
Ethanol : 5 mg/mL (11.72 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (1.17 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 0.5 mg/mL (1.17 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Park HJ, et al. β-Amyrin Ameliorates Alzheimer's Disease-Like Aberrant Synaptic Plasticity in the Mouse Hippocampus. Biomol Ther (Seoul). 2019 Jul 30. [Content Brief]
[2]. Krishnan K, et al. Anti-inflammatory potential of β-amyrin, a triterpenoid isolated from Costus igneus. Inflammopharmacology. 2014 Dec;22(6):373-85. [Content Brief]
[3]. Cai Z, Liu J, et al. β-Amyrin ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress in mice. Pak J Pharm Sci. 2023 Mar;36(2):431-436. [Content Brief]
[4]. Han G, et al. Antibacterial Mode of Action of β-Amyrin Promotes Apoptosis-Like Death in Escherichia coli by Producing Reactive Oxygen Species. J Microbiol Biotechnol. 2022 Dec 28;32(12):1547-1552. [Content Brief]
[5]. Ching J, et al. Quantification of α- and β-amyrin in rat plasma by gas chromatography-mass spectrometry: application to preclinical pharmacokinetic study. J Mass Spectrom. 2011 May;46(5):457-64. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL | 58.5864 mL |
| 5 mM | 0.4687 mL | 2.3435 mL | 4.6869 mL | 11.7173 mL | |
| 10 mM | 0.2343 mL | 1.1717 mL | 2.3435 mL | 5.8586 mL |
β-Amyrin Related Classifications
HY-N2922 Related Classifications
Powered by Bioz